TrialsgrambetaRCTs are beautiful

KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

This guideline cites 2 of the 58 landmark trials in our Nephrology register.

Issued by
KDIGO
Year
2025
Source
Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. Kidney Int. 2025;107(2S):S1–S239.doi 10.1016/j.kint.2024.07.009

Released in January 2025, this is KDIGO's first guideline dedicated to ADPKD. It covers genetic testing and imaging-based prognostication (Mayo imaging classification, PROPKD score), blood-pressure management, pain and cyst infection, polycystic liver disease, extrarenal manifestations, pregnancy and kidney replacement therapy. The one disease-modifying drug it can recommend is tolvaptan, reserved for patients at high risk of rapid progression — the two register trials below define that population and its eGFR range. Note that ADPKD was an exclusion criterion in SPRINT and in the major SGLT2-inhibitor CKD trials, so those recommendations do not transfer.

Tolvaptan in early ADPKD (CKD G1–G3)1

  • 2012TEMPO 3:4⁠Nephrology · Cystic · ADPKDIn 1,445 patients with autosomal dominant polycystic kidney disease, tolvaptan slowed total kidney-volume growth compared with placebo.Read →

Tolvaptan in later-stage ADPKD (CKD G2–G4)1

  • 2017REPRISE⁠Nephrology · Cystic · ADPKDIn 1,370 patients with later-stage ADPKD, tolvaptan slowed eGFR decline compared with placebo.Read →

Cited landmark trials not yet in the register5

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2014HALT-PKD A & B

    Intensive blood-pressure control and dual RAS blockade in ADPKD — the basis of the guideline's blood-pressure advice.

  • 2018TEMPO 4:4

    Open-label extension of TEMPO 3:4 showing sustained tolvaptan effect.

  • 2018DIPAK-1

    Lanreotide did not slow eGFR decline — against somatostatin analogues for kidney protection.

  • 2013ALADIN

    Octreotide slowed kidney-volume growth but not function loss.

  • 2010SUISSE ADPKD

    Sirolimus did not slow cyst growth.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.